china
New Drug Application for a potential First in Class GKA dorzagliatin accepted by NMPAExpansion of indications for dorzagliatin strengthened R&D pipelineSHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). During the Reporting Period, the New Drug Application (NDA) of the first glucokinase activator (GKA) dorzagliatin, has been accepted by The Center for Drug Evaluation (CDE) of the China National Medical Pro...
ACN Newswire
Unaudited Consolidated Profit Attributable to Owners of the Company Amounts to Approximately HK$100 million
HONG KONG, Aug 9, 2021 - (ACN Newswire) - Value Convergence Holdings Limited (VC Holdings, together with its subsidiaries, the Group; HKG:821) announced that, based on its preliminary assessment of the unaudited consolidated financial statements of the Group for the six months ended 30 June 2021 (Reporting Period), the Group is expected to turnaround and record an unaudited consolidated profit attributable to owners of the Company of approximately HK$100 million for the Reporting Period as compared to that of a loss of approximately HK$55 million for the same period last year. The turnaround i...
ACN Newswire
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら